communicable diseases. Thus, the public health interests of the MRC and the Ministry were close, as they had been since the original concordat in 1920 when the MRC was instituted by Royal Charter. The Ministry's priorities were for the quick, safe and effective introduction of the new remediesl. Dick was thus much involved with the clinical and statistical staff, organizing controlled trials of streptomycin and BCG, of whooping cough vaccine, and of Salk and Sabin vaccines against poliomyelitis. He also played a large part in the MRC's work in setting up interests. Whilst the molecular biology and other basic research support was highly successful, George Godber as Chief Medical Officer was becoming increasingly concerned that so little funding was going to applied researchalthough, as Whitehead noted2, important clinical research was being conducted by the MRC in the areas of mental disease, care of the elderly, virus diseases, sexually transmitted diseases, screening for cancer, and nutrition. For the Ministry it was felt that the epidemiological and social aspects should be explored in greater depth and to this end the Department put in shared funds with the MRC. This was really the start of an independent health and social services programme financed by the Ministry: how odd, Dick remarked, that this had to wait 15 years after the creation of the NHS, unless one bore in mind the urgency of other claims for attentionl. It was thus, in mid-1962, that George Godber enlisted Dick's experience to forge a new and expanded research organization for the DHSS.
AT THE MINISTRY
If anyone could have made Alexander Fleming House a jolly place (which is doubtful) it would have been Dick Cohen; to hear his buoyant voice booming down the corridors was itself a tonic. The grim towerblock had the reverse effect; for some reason known only to architectural aficionados, its creator, Erno Goldfinger, was awarded Civic Trust approval. Nevertheless, work under Dick's guidance began and continued with enthusiasm. With a small Civil Service team, partly professional and partly administrative, he set about commissioning health-care studies aimed at precise and practical relevance to the NHS. In this Dick was greatly helped by his previous contacts in the MRC. One, Archie Cochrane, by then Director of the MRC Epidemiology Research Unit and an old friend from King's days, became interested in health-care research and instituted several studies particularly in the field of screening, such as cervical cytology, anaemia and chronic glaucoma. Also, as a foremost proponent of randomized controlled trials (RCT), he and Gordon Mather in Bristol carried out a trial on home versus hospital treatment for myocardial infarction3. The results showed no advantage for hospital care, but the numbers were small and the trial failed to convince cardiologists, who were already setting up hospital coronary care units. Another important contact was Alan Williams, professor in economics at the University of York. This led to extensive work in a new field for the NHS, health economics. A particular interest of Alan Williams was in measures of outcome and of quality of life, as opposed to the old simple measure of mortality. The work of the York School has had wide relevance for the NHS. By some 260 projects and programmes being supported, but eight units had been set up, with directors in university departments, hospitals or other research centres. For example, Walter Holland's Social Medicine and Health Services Research Unit at St Thomas's Medical School was engaged by 1973 in sixteen projects, most on the Unit's initiative but guided by an advisory committee on which the Department was represented. One such study, for which there was some political urgency, was of the effectiveness of multiple screening in general practice4. The results showed no significant difference between screened and control groups of respondents. If, without an RCT, multiphase screening had been made available to the whole middleaged population the cost to the NHS would have been enormous.
After Dick's arrival from the MRC and the start of a small medical research section in 1962, expenditure from the so-called CMO's Fund of £5000 a year was rapidly increased. By 1972-1973 funding (including medical, social science and operational research and development) had reached nearly £3.5 million. Questions were arising, had already arisen, about the Department's policy on research and its control of priorities. The Rothschild Green Paper had come out in November 19715 followed by the White Paper in July 19726. Dick had had discussions with Lord Rothschild in anticipation of the Green Paper and was in principle in favour of the proposed 'customer/contractor' relationship1 7. In Porfoliofor Health I he had already argued against an independent Health Services Research Council as suggested in some quarters8. While it can be said that an independent body would be free from political pressure and administrative expediency, and that the quality of research would be better assured, the case for keeping the research programme within the Department had the merit of 'ensuring that research is undertaken into the value and management of potential new advances' (Dick's own words). However, he favoured the introduction of outside experts as members of Departmental committees 'responsible for reviewing and guiding the general strategy of the programme'. This was in anticipation of the White Paper of July 1972, which led to Dick's appointment as the first Chief Scientist at Deputy CMO level with direct access to the Permanent Secretary. In Portfoliofor Health 2 he outlined the committee structure developed by a small team and agreed in advance with Douglas Black, who succeeded to the Chief Scientist post after Dick's retirement in 1973.
What happened after his retirement? Douglas Black made strenuous efforts to make the over-complex committee system work. But there was a 'black hole' in the system; the development of research policy and the identification of research needs lacked the necessary machinery. Ideally, the new NHS Management Board would have given the Chief Scientist's organization its brief; 1971 research activity had moved swiftly; not only were but with the Board's problems in reorganization of the NHS this does not seem to have happened. As Archie Cochrane writes in his autobiography, 'I was given a position on the senior advisory committee, but the whole set up was a flop and was for me and many others a most depressing experience'9. There is a full discussion of the problems of research policy development in the Nuffield Provincial Hospitals Trust's report Five Years After2 and in Dick's and Walter Holland's essays in the same seriesl. That was in 1981, eight years after Dick had retired from the DHSS. He had continued to keep in touch with the unrolling of events: on the return of the £5 million 'transferred funds' to the
